Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb Randomized, Double Blind, Comparative Study to Assess the Efficacy, Safety, Tolerability and Inhibition of Ovulation of Two Continuous Regimens of Oral Daily 5 mg or 10 mg of Ulipristal Acetate (UPA), Versus a Dose of 5.0mg UPA for 24/4 Days

NCT01953679 is registered in ClinicalTrials.gov with Premier Research as lead sponsor.

NCT NCT01953679
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01953679 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb Randomized, Double Blind, Comparative Study to Assess the Efficacy, Safety, Tolerability and Inhibition of Ovulation of Two Continuous Regimens of Oral Daily 5 mg or 10 mg of Ulipristal Acetate (UPA), Versus a Dose of 5.0mg UPA for 24/4 Days
Lead sponsor
Premier Research
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2014
Completion date
November 30, 2015
Enrollment
180 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

focus: estrogen-free oral contraception